MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
  • Cardiovascular
  • Orthopedics
  • Wall Street Beat
    • Funding Roundup
    • Mergers & Acquisitions
  • Podcasts
    • MPR: Breakthrough Products Series
  • Resources
    • About MassDevice
    • Newsletter Signup
    • Job Board
    • Leadership in Medtech
    • Manufacturer Search
    • Videos
    • Whitepapers
  • DeviceTalks

Biogen to sell Denmark-based manufacturing site to FujiFilm for $890m

March 13, 2019 By Fink Densford Leave a Comment

Biogen (NSDQ:BIIB) said yesterday that it inked an $890 million deal to sell a Denmark-based manufacturing site to Fujifilm (TSE:4901). The site, located in Hillerød, includes a biologics production facility with assembly, labeling and packing capabilities as well as quality control laboratories and warehouses, Cambridge, Mass.-based Biogen said. The facility also has approximately 800 employees who are […]

Filed Under: Business/Financial News Tagged With: Biogen, Fujifilm

Report: Pharma companies kick off new year with price hikes

January 2, 2019 By Sarah Faulkner Leave a Comment

Major pharmaceutical firms started the new year by hiking the prices of hundreds of drugs, according to a new study published by Rx Savings Solutions. First reported in The Wall Street Journal, the study found that the average price increase taken by more than three dozen companies was roughly 6.3%. Get the full story at our […]

Filed Under: Business/Financial News, Pharmaceutical, Wall Street Beat Tagged With: Allergan, Biogen, Bristol-Myers Squibb Co., Eli Lilly & Co., Pfizer

Report: Biogen CEO eyes medical device market

July 23, 2018 By Sarah Faulkner Leave a Comment

After taking the helm at Biogen (NSDQ:BIIB) in 2016, Michel Vounatsos made use of acquisitions and geographic expansion to grow the company. Now, Vounatsos is reportedly considering another possible opportunity to differentiate the pharmaceutical player. The company’s chief executive hinted in an interview with Globes that Biogen could make a move into the medical technology space. Get the full […]

Filed Under: Drug-Device Combinations, Neurological, Pharmaceutical, Wall Street Beat Tagged With: Biogen

After 20 years, Paratek’s broad-spectrum antibiotic is headed to the FDA

February 15, 2018 By Sarah Faulkner Leave a Comment

More than two decades after it was first synthesized in a lab, omadacycline is finally being reviewed by the FDA for its potential as a broad-spectrum antibiotic. It’s a long-awaited milestone for Dr. Evan Loh, who serves as president, COO and CMO of Paratek Pharmaceuticals (NSDQ:PRTK), the company developing and commercializing omadacycline. It’s also emblematic of why […]

Filed Under: Food & Drug Administration (FDA), Hospital Care, Pharmaceutical, Wall Street Beat Tagged With: Biogen, paratekpharmaceuticals

Tandem’s finance chief to retire at year’s end | Personnel Moves – Dec. 8, 2017

December 8, 2017 By Sarah Faulkner Leave a Comment

Tandem Diabetes Care (NSDQ:TNDM) announced today that its EVP and chief financial exec, John Cajigas, will retire at the end of 2017. The company’s SVP of finance, Leigh Vosseller, is slated to take his place effective Jan. 1. Tandem noted that Cajigas’ retirement is not due to any disagreement or problem with the company’s accounting or […]

Filed Under: Drug-Device Combinations, Pharmaceutical, Wall Street Beat Tagged With: Aerie Pharmaceuticals, biofilm, Biogen, Fractyl Laboratories, novabay, tandemdiabetes

Kala Pharmaceuticals taps biopharma exec as chief operating officer | Personnel Moves – Nov. 27, 2017

November 27, 2017 By Sarah Faulkner Leave a Comment

Kala Pharmaceuticals (NSDQ:KALA) this month expanded its team of C-suite executives, naming Todd Bazemore as chief operating officer. Bazemore has spent more than 20 years in the biopharmaceutical industry, most recently working as EVP and COO for Santhera Pharmaceuticals. He has also spent time at Dyax Corp., Sunovion Pharmaceuticals, and Muro Pharmaceuticals. “We welcome Todd to […]

Filed Under: Drug-Device Combinations, Pharmaceutical, Wall Street Beat Tagged With: Biogen, Eli Lilly & Co., Gamida Cell, Kala Pharmaceuticals, Personnel Moves, pertinaxpharma, Pfizer

Biotech, pharma chime in over Trump’s move to halt immigration program

September 6, 2017 By Sarah Faulkner Leave a Comment

On Tuesday, biotech and pharmaceutical companies urged president Donald Trump to reconsider his decision to end former president Barack Obama’s policy protecting undocumented immigrants who arrived in the U.S. as children. Attorney general Jeff Sessions said Tuesday morning that Trump would move to halt the Deferred Action for Childhood Arrivals program in six months, unless […]

Filed Under: Biotech, Legal News, Pharmaceutical, Wall Street Beat Tagged With: Acorda Therapeutics, Alnylam Pharmaceuticals Inc., Bigfoot Biomedical, Biogen, decibeltherapeutics, Juno Therapeutics, ovidtherapeutics

House Dems launch MS drug pricing probe

August 17, 2017 By Sarah Faulkner Leave a Comment

Democrats from the House Committee on Oversight and Government Reform have sent letters to seven drugmakers as part of an investigation into why prices for multiple sclerosis drugs have nearly quadrupled since 2004. Reps. Elijah Cummings (D-Md.) and Peter Welch (D-Mass.) penned inquiries to Bayer, Biogen, EMD Serono, Novartis, Roche, Sanofi-Aventis and Teva Pharmaceuticals. Get […]

Filed Under: Legal News, Pharmaceutical, Wall Street Beat Tagged With: Bayer, Biogen, Capitol Hill, Novartis, Roche, Sanofi-Aventis, Teva Pharmaceuticals

Biogen lifts outlook after strong Q2

July 25, 2017 By Sarah Faulkner Leave a Comment

Shares in Biogen (NSDQ:BIIB) rose today after the biopharmaceutical company met expectations on Wall Street with its second quarter results. The Cambridge, Mass.-based company posted profits of $863 million, or $4.07 per share, on sales of $3.1 billion for the 3 months ended June 30, for bottom-line loss of -18% on sales growth of 6% compared with […]

Filed Under: MassDevice Earnings Roundup, Pharmaceutical, Wall Street Beat Tagged With: Biogen

Ocular Therapeutix founder & CEO Sawhney to step down | Personnel Moves – April 13, 2017

June 23, 2017 By Sarah Faulkner Leave a Comment

The president & CEO of Ocular Therapeutix (NSDQ:OCUL), Amarpreet Sawhney, is slated to step down from the company that he helped start in 2006. He will serve as the board’s executive chairman for 1 year, unless he decides to leave earlier. The company wrote in a regulatory filing that “his service will be automatically renewed for […]

Filed Under: Drug-Device Combinations, Pharmaceutical, Wall Street Beat Tagged With: Biogen, Bristol-Myers Squibb Co., etonpharmaceuticals, Nanotherapeutics, Novartis, oculartherapeutix, Personnel Moves, Pulmatrix Inc., Valeant Pharmaceuticals

Braeburn names former Teva exec as new president, CEO | Personnel Moves – June 14, 2017

June 14, 2017 By Sarah Faulkner Leave a Comment

Braeburn Pharmaceuticals said last week that it named Michael Derkacz as president and CEO of the buprenorphine implant-maker. Most recently, Derkacz worked as senior VP and head of global central nervous system and pain therapeutic areas for Teva Pharmaceuticals (NYSE:TEVA). Behshad Sheldon, who helped to found Braeburn in 2012, is slated to step down from Braeburn […]

Filed Under: Blog Tagged With: alexionpharmaceuticals, AstraZeneca plc, Biogen, Braeburn Pharmaceuticals, cytrx, Dicerna Pharmaceuticals, Merrimack Pharmaceuticals, Novartis, oculartherapeutix, Sanofi-Aventis, uniqure

  • 1
  • 2
  • 3
  • Next Page »
Need Medtech news in a minute?
We Deliver!

MassDevice Enewsletters get you caught up on all the mission critical news you need in med tech. Sign up today.

Popular Posts

  • Report: SEC probes GE Healthcare, Philips, Siemens in Chinese bribery scheme
  • Edwards Lifesciences warns against below-market mini-tender offer Edwards Lifesciences
  • J&J’s Ethicon files ITC complaint against Intuitive Surgical Intuitive Surgical's EndoWrist instruments
  • Auris Health loses motion to move Intuitive Surgical patent suit from Del. to Cali. Johnson & Johnson's Auris, Intuitive Surgical
  • Enable Injections inks deal with Sanofi for drug delivery platform enfuse-enable-injections
Tweets by @MassDevice
MDO ad

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion

MASSDEVICE

Subscribe to MassDevice
Advertise with us
About
Contact us
Add us on FacebookMassDevice Network
Follow us on Twitter@MassDevice
Connect with us on LinkedInLinkedIn
Follow us on YouTube YouTube

Copyright © 2019 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Advertise | Privacy Policy | RSS